title: Screening for radiation sensitizers of Drosophila checkpoint mutants.
abstract: Anti-cancer therapy is largely comprised of radiation, surgery, and chemotherapy treatments. Although a single mode of therapy can be effective in treating certain types of cancer, none presents a cure. Multi-modal therapy, the use of two or more agents in combination (e.g., radiation and chemotherapy together), shows potential for a more effective treatment of cancer. The challenge then is identifying effective therapy combinations. In this chapter, we describe the use of Drosophila as a whole animal in vivo model to screen for small molecules that effectively combine with ionizing radiation to kill checkpoint mutants preferentially over wild-type. The differential use of wild-type and checkpoint mutants has the potential to identify molecules that act in a genotype-specific manner to eradicate checkpoint mutant tissues when combined with radiation, while sparing wild-type tissues.
authors.affiliation: Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, CO, USA. Mara.Stewart@Colorado.EDU
authors.forename: Mara
authors.initials: M
authors.lastname: Gladstone
authors.forename: Tin Tin
authors.initials: TT
authors.lastname: Su
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D003131:Combined Modality Therapy; D004330:Drosophila / Q000187:drug effects* / Q000235:genetics* / Q000528:radiation effects; D004625:Embryo, Nonmammalian / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D009154:Mutation; D011839:Radiation, Ionizing; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents